Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
6 Results for "
IMQ
" in MedChemExpress (MCE) Product Catalog:
Products (6)
6 Results for "IMQ" in MCE Product Catalog:
Target:
Research Areas:
RIPK1-IN-19 is a selective RIPK1 inhibitor (IC50=15 nM). RIPK1-IN-19 does not show obvious activity against RIPK2, RIPK3, and RIPK4. RIPK1-IN-19 displays potent protective activity in TNFα-induced systemic inflammatory response syndrome (SIRS) model and Imiquimod (IMQ)-induced psoriasis model. RIPK1-IN-19 can be used in research on inflammation and immune system diseases .
Target:
Research Areas:
12R-LOX-IN-2 (compound 7b) is an inhibitor of 12R-lipoxygenase (12R-LOX). 12R-LOX-IN-2 inhibits imiquimod (IMQ)-induced hyperproliferation of psoriatic keratinocytes and suppresses colony formation. 12R-LOX-IN-2 also reduced the protein level of Ki67 and the mRNA expression of IL-17A in IMQ-induced cells. 12R-LOX-IN-2 can be used in research into psoriasis and other skin-related inflammatory diseases .
Cat. No.: HY-155505
CAS No.: 2953023-30-6
Target:
Research Areas:
AHR agonist 4 (compound 24e) is an agonist of Aryl hydrocarbon receptor (AHR), assocaited with the immune balance of Th17/22 and Treg cells. AHR agonist 4 serves as a lead compound for anti-psoriasis drug, alleviates imiquimod (IMQ)-induced psoriasis-like skin lesion . AHR agonist 4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Cat. No.: HY-161864
CAS No.: 2256751-16-1
Target:
Research Areas:
STAT3-IN-29 (Compound B20) is an inhibitor for STAT3. STAT3-IN-29 inhibits the proliferation of HaCaT cell with IC50 of 0.09 µM, ameliorates the IMQ-induced psoriasis in mouse models .
Cat. No.: HY-175782
Target:
Research Areas:
SMU-R39 is a TLR7 and TLR8 antagonist with IC50 values of 3.22 μM and 0.24 μM, respectively. SMU-R39 binds to recombinant mTLR7 protein (KD = 2.36 μM) and to recombinant hTLR8 protein (KD = 105 nM). SMU-R39 suppresses downstream NF-κB and MAPK signaling, and reduces secretion/transcription of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in PBMCs and THP-1 cells. SMU-R39 demonstrates anti-inflammatory efficacy in Imiquimod (IMQ) (HY-B0180)-induced psoriasis mouse model. SMU-R39 can be used for the study of autoimmune diseases such as psoriasis .
Cat. No.: HY-189757
Research Areas:
CDK8/19-IN-4 is an orally active CDK8/19 inhibitor. CDK8/19-IN-4 directly binds to and inhibits CDK8/Cyclin C, and inhibits CDK19/Cyclin C. The IC50 values of CDK8/19-IN-4 for CDK8, CDK19, CDK7, and CDK6 are 24.5 nM, 38.6 nM, 412.5 nM, and 694.4 nM, respectively, and the Kd for CDK8 is 46.44 nM. CDK8/19-IN-4 promotes Treg differentiation through the STAT1 and TGF-β/Smad signaling pathways, reduces STAT1 phosphorylation and enhances Smad2/3 activation, and inhibits IL-17A/TNF-α-induced keratinocyte proliferation and inflammatory mediator production. CDK8/19-IN-4 alleviates skin inflammation in the IMQ-induced psoriasis-like model. CDK8/19-IN-4 can be used for research on psoriasis .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
